Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2014-07-01 Director's Dealing
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2014-07-01 English
3
Director's Dealing
2014-07-01 English
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement filed on Form S-1. It discusses the distribution of a Preliminary Prospectus and requests acceleration of the effectiveness of the Registration Statement. This is related to the process of securities registration and underwriting, not a financial report or earnings release. The document is short (1591 characters) and is a correspondence related to a capital raising process. Therefore, it fits best under Capital/Financing Update (CAP) as it pertains to fundraising activities and registration statement acceleration.
2014-06-30 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Minerva Neurosciences to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses procedural matters related to the registration statement becoming effective. The document is short (2324 characters) and does not contain financial data or report content itself. It is an official communication related to a regulatory filing but not the filing or report itself. Therefore, it fits best under Regulatory Filings (RNS) as a procedural correspondence regarding a registration statement.
2014-06-30 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) filed pursuant to Rule 433, dated June 30, 2014, relating to a preliminary prospectus and registration statement for an initial public offering (IPO) by Minerva Neurosciences, Inc. It contains detailed information about the offering, including the number of shares offered, pricing, use of proceeds, insider participation, and summary historical financial data. The document is not a full annual or quarterly report but rather a detailed offering document related to capital raising. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains substantive financial and offering details, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2014-06-30 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 3 to Form S-1 Registration Statement filed with the SEC, dated June 30, 2014, for Minerva Neurosciences, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes details about the offering, underwriting, risk factors, and other disclosures typical of a registration statement/prospectus. This is not a financial report like an annual or quarterly report, nor is it a transcript, audit, or management report. It is a capital markets filing related to the company's fundraising and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, supporting a high confidence level.
2014-06-30 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.